Eteplirsen regulatory update

Sarepta said FDA granted rare pediatric disease designation to eteplirsen to treat patients with Duchenne Muscular Dystrophy (DMD) who are amenable to skipping exon 51. Under the FDA’s Rare Pediatric ...